NCT02105129View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

PHASE1CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

HMPL-523

HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA

DRUG

Placebo

Oral administration

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

All Listed Sponsors

lead

Hutchison Medipharma Limited

INDUSTRY

NCT02105129 - A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 | Biotech Hunter | Biotech Hunter